TheraCryf (FRA:8EV) Interest Expense : €0.00 Mil (TTM As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is TheraCryf Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. TheraCryf's interest expense for the six months ended in Sep. 2023 was € 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2023 was €0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. TheraCryf's Operating Income for the six months ended in Sep. 2023 was € -1.69 Mil. TheraCryf's Interest Expense for the six months ended in Sep. 2023 was € 0.00 Mil. TheraCryf has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

TheraCryf Interest Expense Historical Data

The historical data trend for TheraCryf's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TheraCryf Interest Expense Chart

TheraCryf Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Interest Expense

Get a 7-Day Free Trial

TheraCryf Semi-Annual Data
	Mar13	Mar14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

TheraCryf Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

TheraCryf (FRA:8EV) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

TheraCryf's Interest Expense for the six months ended in Sep. 2023 was €0.00 Mil. Its Operating Income for the six months ended in Sep. 2023 was €-1.69 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Sep. 2023 was €0.00 Mil.

TheraCryf's Interest Coverage for the quarter that ended in Sep. 2023 is calculated as

TheraCryf had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

TheraCryf PLC has no debt.

TheraCryf (FRA:8EV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TheraCryf PLC (FRA:8EV) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

EVG:UK

Address

Congleton Road, Suite 24G13- Block 24, Alderley Park, Nether Alderley, GBR, SK10 4TG

Website

https://www.evgen.com

Evgen Pharma PLC is a UK-based clinical-stage drug development company. The company is focused on the development of sulforaphane-based compounds. Its core technology is Sulforadex, which synthesis and stabilizes the naturally occurring compound sulforaphane. Geographically, the company operates only in the United Kingdom. It is engaged in the treatment of breast cancer and Subarachnoid Haemorrhage.

TheraCryf (FRA:8EV) Headlines

No Headlines